These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28643370)

  • 1. Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.
    Hamuro L; Chan P; Tirucherai G; AbuTarif M
    CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):596-603. PubMed ID: 28643370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence JM; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz S
    Muscle Nerve; 2013 Sep; 48(3):343-56. PubMed ID: 23681930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.
    Mazzone E; Vasco G; Sormani MP; Torrente Y; Berardinelli A; Messina S; D'Amico A; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Gasperini S; Previtali S; Napolitano S; Martinelli D; Bruno C; Vita G; Comi G; Bertini E; Mercuri E
    Neurology; 2011 Jul; 77(3):250-6. PubMed ID: 21734183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the six-minute walk test to characterize golden retriever muscular dystrophy.
    Acosta AR; Van Wie E; Stoughton WB; Bettis AK; Barnett HH; LaBrie NR; Balog-Alvarez CJ; Nghiem PP; Cummings KJ; Kornegay JN
    Neuromuscul Disord; 2016 Dec; 26(12):865-872. PubMed ID: 27818009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy.
    Kempen JC; Harlaar J; van der Kooi AJ; de Groot IJ; van den Bergen JC; Niks EH; Verschuuren JJ; Brehm MA
    Neuromuscul Disord; 2014 Mar; 24(3):216-21. PubMed ID: 24365209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Atkinson L; Elfring GL; Reha A; Miller LL
    Muscle Nerve; 2010 Dec; 42(6):966-74. PubMed ID: 21038378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance.
    Oreto L; Vita GL; Mandraffino G; Carerj S; Calabrò MP; Manganaro R; Cusmà-Piccione M; Todaro MC; Sframeli M; Cinquegrani M; Toscano A; Vita G; Messina S; Zito C
    Acta Myol; 2020 Dec; 39(4):191-199. PubMed ID: 33458574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Exercise-Induced Fatigue a Problem in Children with Duchenne Muscular Dystrophy?
    Blaschek A; Rodrigues M; Ille L; Idriess M; Well T; Warken B; Müller C; Hannibal I; Tacke M; Müller-Felber W; Vill K
    Neuropediatrics; 2020 Oct; 51(5):342-348. PubMed ID: 32369835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.